MARKET

IRON

IRON

Disc Medicine Inc
NASDAQ
60.09
-1.92
-3.10%
After Hours: 60.09 0 0.00% 16:34 03/27 EDT
OPEN
62.20
PREV CLOSE
62.01
HIGH
62.34
LOW
60.00
VOLUME
318.20K
TURNOVER
--
52 WEEK HIGH
99.50
52 WEEK LOW
30.82
MARKET CAP
2.29B
P/E (TTM)
-9.9957
1D
5D
1M
3M
1Y
5Y
1D
Wedbush Keeps Their Buy Rating on Disc Medicine (IRON)
TipRanks · 2d ago
Disc Medicine completes Phase 3 APOLLO enrollment for bitopertin in EPP; trial size grows to 183 participants
Reuters · 3d ago
Disc Medicine completes enrollment in APOLLO trial
TipRanks · 3d ago
Disc Medicine Doses Last Patient In Pivotal Phase 3 APOLLO Study Of Bitopertin In Erythropoietic Protoporphyria
Benzinga · 3d ago
DISC MEDICINE ANNOUNCES COMPLETION OF ENROLLMENT OF PHASE 3 APOLLO TRIAL OF BITOPERTIN IN ERYTHROPOIETIC PROTOPORPHYRIA
Reuters · 3d ago
DISC MEDICINE INC - APOLLO STUDY RESULTS EXPECTED IN Q4 2026
Reuters · 3d ago
Weekly Report: what happened at IRON last week (0316-0320)?
Weekly Report · 6d ago
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation – IRON
Barchart · 03/19 11:56
More
About IRON
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.

Webull offers Disc Medicine Inc stock information, including NASDAQ: IRON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRON stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IRON stock methods without spending real money on the virtual paper trading platform.